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Abstract
Background: Fungal keratitis is one of the major causes of infectious keratitis in tropical countries. Symptoms of
fungal keratitis consist of blurred vision, redness, tearing, photophobia, pain and foreign body sensation. If not
treated effectively, it could lead to blindness. Common causes include Candida spp., Fusarium spp. and Aspergillus
spp.. With the limited choices of topical antifungal agents, we were faced with Cladosporium keratitis, a rare cause
of fungal keratitis.
Case presentation: A 62-year-old Asian male construction worker came to us with intense ocular pain,
injection of the conjunctiva, blurred vision, and foreign body sensation in his left eye. His visual acuity was
20/40 OD and 20/400 OS. Slit-lamp exam revealed a corneal ulcer with feathery margin and Descemet’s
membrane folding. The culture yielded Cladosporium species.. The patient did not show improvements after
applying topical natamycin (5 %), topical amphotericin B (1mg/ml), topical fluconazole (2mg/ml) and oral
ketoconazole (200mg). After shifting the medical regimen to voriconazole via topical and systemic routes
(1mg/ml and 200mg respectively), the keratitis was controlled.
Conclusions: Fungal keratitis remains a challenge for ophthalmologists as there is no evidence suggesting
any particular drug or combination of drugs is more effective than another. A review of common topical
antifungal agents was done. Voriconazole could be a good choice for treating corneal infection by
Cladosporium species.
Background
Fungal infections occur in countries with warmer cli-
mates. Any agent capable of infecting humans is a po-
tential infectious agent. Some common causes include
Candida spp. (yeast), Fusarium spp. (filament) and As-
pergillus spp. (filament) (Table 1). According to relative
incidence reports from India, approximately 45 % of all
central corneal ulcers are cause by fungi [1]. Cladospor-
ium spp. are rare causes of fungal keratitis. They are As-
comycota fungi that are commonly found on plants. The
air borne spores make them extremely abundant in out-
door air. Indoors they can be found on moist surfaces.
Though rarely pathogenic to humans, they can be causa-
tive agents of pulmonary infections, skin lesions, onycho-
myocosis and keratitis [2]. Fungi are able to gain access
into the corneal stroma via multiple routes [3]. A previous
epithelial defect or a penetrating injury could allow fungi
to enter through the epithelium. Fungal endophthalmitis
could invade from the posterior segment through the
Descemet’s membrane. In the case of trabeculectomy,
the corneo-scleral meshwork becomes a passage for
microorganisms. Once within the cornea, fungi can
proliferate and spread through the channels. The pro-
teolytic enzymes and mycotoxins can then cause tis-
sue damage. Predisposing factors of fungal keratitis
include ocular trauma, contact lens wear, pre-existing
corneal surface disease, underlying systemic disease
(e.g., diabetes mellitus) and prolonged use of immu-
nosuppressant and antibiotics [4]. It is usually charac-
terized by stromal inflammation. If left untreated, it
could lead to corneal scarring which could ultimately
result in blindness [5].
Natamycin is the only drug approved by the United
States Food and Drug Administration for treating
fungal keratitis. Reports on Cladosporium corneal
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infection have been scarce [6]. The patient was refrac-
tory to a combination of topical and systemic agents.
After switching to voriconazole, we have successfully
treated our patient.
Case presentation
The patient was a 62-year-old Asian male construc-
tion worker who worked in a dusty environment.
Debris made up of cement hit his left eye during
work on the 22nd of November 2014. He experi-
enced intense, sharp, and constant pain. Blurred
vision, red eye and foreign body sensation were the
main clinical manifestations. Photophobia, swelling
and watery discharge were also noted. He was
referred to our hospital from a local medical clinic 4
days after the incident. His integumentary system
was intact without signs of fungal infection. Accord-
ing to the patient’s statement, he had hypertension
and diabetes mellitus under medical control for
years. He was not a user of contact lenses. The
patient claimed that he had a fungal keratitis in his
left eye 10 years ago after trauma. Natamycin was
used for more than 3 months during that episode.
The ocular examination showed his visual acuity to
be 20/40 OD and 20/400 OS. The intraocular pres-
sure (IOP) was 15 mmHg OD and 15 mmHg OS.
There was a 3×3 mm2 epithelial defect with stromal
infiltration on the inferior medial area of the left
cornea (Fig. 1). The corneal ulcer was found with
feathery margin and Descemet’s membrane folding.
Ring infiltration was also present. Few fine pigmen-
tary keratic precipitate (KP) and flare were found
behind the area of cornea ulcer. The anterior cham-
ber was deep and clear without hypopyon. There
was mild nuclear sclerosis of cataract. The vitreous
was clear without signs of endophthalmitis. Corneal
scraping was done for smear and culture. Under the
direct microscopic examination with lactophenol cot-
ton blue (LPCB) wet mount preparation, yeast was
present. Repeated cultivations were done on 5 %
sheep blood, chocolate, anaerobic blood agar, inhibi-
tory mold agar (IMA), IMA supplemented with
chloramphenicol and gentamicin (ICG) agar, and
thioglycollate medium. LPCB mount revealed pig-
mented septate hyphae. Dislodging oval conidia with
dark attachment scars characteristic of Cladosporium sp.
were seen on microscope. Initially the patient was pre-
scribed with natamycin (5 %, QID, Alcon Inc. Texas,
USA) and amphotericin B (1mg/mL, Q2H, BMS New
Table 1 Causative agents for Fungal Keratitis
Filamentous fungi
Hyaline fungi Molds Dematiaceous fungi
Common Common
Fusarium spp Curvularia spp
Aspergillus spp Uncommon
Uncommon Bipolaris spp
Acremonium spp Exserohilum spp
Chrysosporium spp Cladosporium spp





Fig. 1 Fungal keratitis caused by Cladosporium sp. An external photograph of the left eye of a 62-year-old male construction worker with
Cladosporium keratitis. This photograph was taken 4 days after trauma. The corneal ulcer was found with feathery margin and Descemet’s
membrane folding. Ring infiltration was also present
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York City, U.S. ) for yeast infection and levofloxacin
(0.5 %, Q2H, Santen Inc. Japan) for possible concomitant
bacterial infection. Topical fluconazole (2mg/mL, Q2H,
Pfizer Inc., New York City, U.S.) and oral ketoconazole
(200mg/tab, BID, Swiss Co., Taiwan) were then added to
the prescription after culture results. Due to the persistent
infection, the anti-fungal agent was shifted to voriconazole
via topical (1mg/mL, Q2H, Pfizer Inc. New York City,
U.S.) and oral routes (200 mg/tab, BID Pfizer Inc. New
York City, U.S.) on the 6th day of admission. For better
drug penetration, soaking was done on the area of the cor-
neal ulcer with voriconazole for 3 min everyday under
local anesthesia. It is then followed by bullous irrigation of
Balance Salts Solution (Alcon Inc. Texus, USA) to prevent
medicamentosa. The symptoms improved 10 days after
admission and the patient was discharged 14 days later.
The patient was discharged with topical voriconazole
(1mg/mL, QID, Pfizer Inc. New York City, U.S.) for 2
weeks to prevent reactivation. 3 months post-treatment
visual acuity was 20/30 OD and 20/40 OS. The IOP was
14 mmHg OD and 14 mmHg OS. Slit lamp biomicro-
scopy of the left eye showed corneal opacity with minimal
infiltration (Fig. 2).
Conclusion
Leber first documented fungal keratitis in 1879 [7, 8].
Fungal keratitis has preponderance in males with a male
to female ratio of 2.25:1 [9]. Molds are far more com-
mon than yeast [10]. Patients with ocular trauma were
5.33 times more likely to develop microbial keratitis [11].
The association of trauma was higher for fungal and para-
sitic keratitis. Out of all fungal keratitis, 81.9 % was caused
by trauma [11]. The reason is obvious in that trauma was
more often associated with outdoor occupation (e.g. agri-
culture and manual labor).
Treating fungal keratitis is a laborious process often
requiring months.
A literature search using “Fungal keratitis”, “Clados-
porium” and “ophthalmic antifungal agents” as keywords
in relevant databases (including Medline, Cochrane
Library, and PubMed) was performed.
Common agents including their dosages and side ef-
fects were gathered and organized (Table 2). Fungal
keratitis can be both treated by medical or surgical ther-
apy. The efficacy of medical treatment depends on the
penetration of the agent into the aqueous humor and
achieving therapeutic levels. Apart from the deep pene-
tration into the cornea by the fungi and the single
commercially available antifungal agent (natamycin),
resistance to treatment also plays a part. The formation
of biofilm is considered to be the cause of resistance
[12, 13]. A systemic review of medical interventions
for fungal keratitis in the Cochrane Database (updated
in 2012) concluded that there is no evidence suggest-
ing that any particular drug or combination of drugs
is more effective than another [14]. However, litera-
tures have been emerging to support the use of sec-
ond generation triazoles, such as voriconazole [6, 15].
Visual acuity and infiltrate size are predictors of
worse clinical outcomes. Patients with infiltrates and
hypopyon are less likely to respond to medical treat-
ment [16, 17].
In a general sense, triazoles were used for yeasts and
amphotericin B was used for molds. A good initial treat-
ment would be a combination of natamycin 5 % drops
and amphotericin B 0.15 % drops. Additional topical,
subconjunctival and or systemic treatment could then be
Fig. 2 Cladosporium keratitis 3 months after treatment. This external eye photograph was taken from the same patient three months after
treatment. The patient’s left eye showed corneal opacity with minimal infiltration
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considered depending on the depth and severity of the
infection and the culture result. The treatment regimen
should be adjusted according to the clinical progression
based on biomicroscopic signs, repeated corneal scrap-
ings and tolerance of medications. It is also important to
put the patient’s compliance into account.
Amphotericin B alters the stability of the membrane by
binding to ergosterol and forms pores. It is insufficiently
absorbed from the GI tract and due to its poor ocular
penetration, administration of higher doses via the intra-
venous route is needed [4]. Amphotericin also binds to
mammalian cholesterol albeit with lower affinity. Thus
explaining its side effects. It causes chills and fever and it
is notorious for its nephrotoxicity [4]. It is the drug of
choice for Candida keratitis. Though also effective against
filamentous fungi, it has no activity against Fusarium sp..
Natamycin is the only ophthalmic agent approved by the
Food and Drug Administration. It also binds to ergosterol.
However, it does not alter the membrane permeability. In
stead, it prevents the ergosterol-dependent fusion of vacu-
oles and membrane fusion and fission [18]. It has good
activity against Candida, Aspergillus and Fusarium spp.
Though being used as a standard care, the penetration is
poor and the bioavailablity is only about 2 % after topical
administration [19]. It is therefore not the drug of choice
for deep, severe infection.
Corticosteroids (imidazoles or triazoles) inhibit sterol
demethylation of lanosterol to ergosterol in fungal mem-
branes. Fluconazole is a safe agent that can be adminis-
tered orally, intravenously, subconjunctivally or topically.
The penetration is well with few side effects [20]. It is lim-
ited by its narrow spectrum of antifungal activity. It is
inactive against Aspergillus and Fusarium spp. Miconazole
has a broad spectrum of activity however, it is toxic
systematically and could lead to epithelial erosions topic-
ally. It is used as a second-line agent to natamycin [21].
Voriconazole was first tested for retinal toxicity in
rodent animal models [22]. No electroretinographic or
histological abnormality was reported with an intravitreal
voriconazole concentrations up to 25 μg/mL. Voricona-
zole has an excellent susceptibility profile against both
yeasts and molds. It does not depend on the state of the
Table 2 Common topical agents for fungal keratitis
Name Species Concentration Dosing interval Side effects Ref.
Polylene drivatives
Amphotericin B Aspergillus, spp. 0.15–0.25 % 1st day: Q30mins Nephrotoxic, bone marrow suppression,
anemia, headache
[1]
Candida spp. 2nd day onward:
Q1H
Natamycin Fusarium spp. 5 % 5 times a day Burning, irritation, punctate keratitis, chemosis [1]
Aspergillus spp.
Candida spp.
Azole – Imidazole derivatives
Miconazole Aspergillus spp. 1 % Q1H Punctate epithelial erosions, pruritus, irritation [2, 3]
Scedosporium spp. Ointment: 2 %
Candida spp.




Econazole Aspergillus spp. 2 % Q4H ~ QID Local irritation [5]
Fusarium spp.
Ketoconazole Aspergillus spp. 1 % QID Gynecomastia, impotence, hepatotoxic [6, 7]
Fusarium spp.
Curvularia spp.
Azole – Triazole derivatives
Fluconazole Filamentous fungi 0.2 % Q4H Irritation, burning sensation [8]
Voriconazole Filamentous fungi 1 % Q1H Visual disturbances, skin rash [9, 10]
Candida spp.
Pyramidine drivatives
Flucytosine Candidda spp. 1 % Q1H Irritation, itching, burning sensation, nausea,
vomit, diarrhea
[11]
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epithelial surface [23]. The ocular penetration of voricona-
zole after two 400mg doses of voriconazole 12 h apart was
measured at 1.13 μg/mL (53 % of plasma levels) [24]. The
safety profile of voriconazole has been reviewed [25].
Visual disturbances including photophobia and/or color
change and skin rashes were mild and transient. Even with
continued therapy, they typically resolve within 1 month.
Oral and IV formulations were approved by FDA for
deadly fungal infections in 2002. The broad spectrum of
antifungal activity includes species that are resistant to
other antifungal agents [24]. In the high-risk group popu-
lation for developing fungal keratitis or endophthalmitis,
voriconazole can also be used as a prophylactic agent [24].
Despite the recent advancement in diagnosis and treat-
ment of fungal keratitis, 15–27 % require surgery [26].
Surgical mode of treatment includes debridement, pene-
trating keratoplasty, evisceration, bandage contact lens
and corneal transplantation. Surgical intervention is car-
ried out in a significantly larger number of patients with
fungal keratitis compared to bacterial and parasitic kera-
titis thus indicating the poor response of fungal keratitis
to medical treatment [11].
In conclusion, voriconazole could be a good choice for
refractory fungal keratitis. We were able to control the
Cladosporium keratitis by combining oral and topical
voriconazole.
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